1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 10, 13/Mar/2025
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection that can lead to complications in risk groups.

Aim

We aimed to estimate the incidence of RSV hospitalisation in adults, determine the risk factors and characterise priority groups for prevention.

Methods

This population-based cohort study included adults 60 years and older in Navarre, Spain, in seasons 2016/17 to 2019/20. We estimated the rate of RSV hospitalisation confirmed by PCR and evaluated risk factors using Poisson regression.

Results

Within 642,622 person-years analysed, we detected 544 RSV hospitalisations (average annual rate: 84.7/100,000). The rate varied among seasons between 59.7 and 95.6 per 100,000. The rate ratio of hospitalisation was higher than 3 from the age of 75 years and around 7 in the 85–94 years age group compared with those aged 60–64 years. Nursing home residence, functional dependence, haematological cancer, chronic obstructive pulmonary disease (COPD), asthma, cardiovascular disease, severe obesity, diabetes and chronic kidney disease were independent risk conditions. Rate of RSV hospitalisation was higher than 300 per 100,000 among people with haematological cancer or nursing home residence, those aged ≥ 75 years with COPD or functional dependence, and those aged ≥ 85 years with asthma or cardiovascular disease. These groups represented 13.2% of all adults aged ≥ 60 years and 50.7% of their RSV hospitalisations. On average, these groups had one RSV hospitalisation per 307 person-years.

Conclusion

Advanced age, in addition to nursing home residence, functional dependence and some comorbidities define priority groups for RSV vaccination.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.10.2400364
2025-03-13
2025-03-17
/content/10.2807/1560-7917.ES.2025.30.10.2400364
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/10/eurosurv-30-10-3.html?itemId=/content/10.2807/1560-7917.ES.2025.30.10.2400364&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Respiratory syncytial virus (RSV) disease. Geneva: WHO. [Accessed: 25 Jan 2025]. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/respiratory-syncytial-virus-disease
  2. Ministerio de Sanidad. Recomendaciones de utilización de nirsevimab frente a virus respiratorio sincitial para la temporada 2023-2024. [Recommendations for the use of nirsevimab against respiratory syncytial virus for the 2023-2024 season]. Madrid: Ministry of Health; 2023. Spanish. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab_2023.pdf
  3. Nowalk MP, D’Agostino H, Dauer K, Stiegler M, Zimmerman RK, Balasubramani GK. Estimating the burden of adult hospitalized RSV infection including special populations. Vaccine. 2022;40(31):4121-7.  https://doi.org/10.1016/j.vaccine.2022.05.077  PMID: 35667912 
  4. Viguria N, Martínez-Baz I, Moreno-Galarraga L, Sierrasesúmaga L, Salcedo B, Castilla J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS One. 2018;13(11):e0206474.  https://doi.org/10.1371/journal.pone.0206474  PMID: 30439987 
  5. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis. 1999;179(1):25-30.  https://doi.org/10.1086/314567  PMID: 9841818 
  6. Jiménez-Jorge S, Delgado-Sanz C, de Mateo S, Pozo F, Casas I, Larrauri A, et al. Vigilancia del virus respiratorio sincitial en el marco del Sistema de Vigilancia de la Gripe en España, 2006-2014. Enferm Infecc Microbiol Clin. 2016;34(2):117-20.  https://doi.org/10.1016/j.eimc.2014.12.012  PMID: 25703209 
  7. McLaughlin JM, Khan F, Schmitt HJ, Agosti Y, Jodar L, Simões EAF, et al. Respiratory syncytial virus-associated hospitalization rates among US Infants: a systematic review and meta-analysis. J Infect Dis. 2022;225(6):1100-11.  https://doi.org/10.1093/infdis/jiaa752  PMID: 33346360 
  8. Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, et al. Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016. Pediatrics. 2020;146(1):e20193611.  https://doi.org/10.1542/peds.2019-3611  PMID: 32546583 
  9. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther. 2023;12(4):1137-49.  https://doi.org/10.1007/s40121-023-00792-3  PMID: 36941483 
  10. Nguyen-Van-Tam JS, O’Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166):220105.  https://doi.org/10.1183/16000617.0105-2022  PMID: 36384703 
  11. Loubet P, Lenzi N, Valette M, Foulongne V, Krivine A, Houhou N, et al. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect. 2017;23(4):253-9.  https://doi.org/10.1016/j.cmi.2016.11.014  PMID: 27903461 
  12. Martinón-Torres F, Gutierrez C, Cáceres A, Weber K, Torres A. How does the burden of respiratory syncytial virus compare to influenza in Spanish adults? Influenza Other Respir Viruses. 2024;18(6):e13341.  https://doi.org/10.1111/irv.13341  PMID: 38923767 
  13. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023;10(11):ofad513.  https://doi.org/10.1093/ofid/ofad513  PMID: 38033988 
  14. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15(1):443.  https://doi.org/10.1186/s12879-015-1218-z  PMID: 26497750 
  15. Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment. Infect Dis Ther. 2021;10(S1) Suppl 1;47-60.  https://doi.org/10.1007/s40121-020-00383-6  PMID: 33656652 
  16. PATH. RSV vaccine and mAb snapshot. Seattle: PATH. [Accessed: 26 Feb 2025]. Available from: https://www.path.org/our-impact/resources/rsv-vaccine-and-mab-snapshot
  17. European Medicines Agency (EMA). Summary of product characteristics. Abrysvo®, Pfizer. Amsterdam: EMA. [Accessed: 20 August 2024]. Available online: https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_en.pdf
  18. European Medicines Agency (EMA). Summary of product characteristics. Aresvy®, GlaxoSmithKline. Amsterdam: EMA. [Accessed: 20 August 2024]. Available online: https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.pdf
  19. European Medicines Agency (EMA). Summary of product characteristics. mResvia®, Moderna. Amsterdam: EMA. [Accessed: 20 September 2024]. Available from: https://www.ema.europa.eu/en/documents/product-information/mresvia-epar-product-information_en.pdf
  20. Teirlinck AC, Broberg EK, Stuwitz Berg A, Campbell H, Reeves RM, Carnahan A, et al. Recommendations for respiratory syncytial virus surveillance at the national level. Eur Respir J. 2021;58(3):2003766.  https://doi.org/10.1183/13993003.03766-2020  PMID: 33888523 
  21. World Organization of Family Doctors (WONCA). International classification of primary care. 2nd edition. Oxford: Oxford University Press; 1998.
  22. Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the advisory committee on immunization practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696-702.  https://doi.org/10.15585/mmwr.mm7332e1  PMID: 39146277 
  23. Government of Canada. (2024). Respiratory syncytial virus (RSV) vaccines: Canadian immunization guide. Ottawa: Government of Canada. [Accessed: 26 February 2025]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html
  24. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427-36.  https://doi.org/10.1093/cid/cis211  PMID: 22495079 
  25. Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European countries: a time series analysis. J Infect Dis. 2022;226(Suppl 1):S29-37.  https://doi.org/10.1093/infdis/jiac150  PMID: 35748871 
  26. Sharp A, Minaji M, Panagiotopoulos N, Reeves R, Charlett A, Pebody R. Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England. Influenza Other Respir Viruses. 2022;16(1):125-31.  https://doi.org/10.1111/irv.12910  PMID: 34658161 
  27. Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H. A Real-world analysis of patient characteristics and predictors of hospitalization among US Medicare beneficiaries with respiratory syncytial virus infection. Adv Ther. 2020;37(3):1203-17.  https://doi.org/10.1007/s12325-020-01230-3  PMID: 32026380 
  28. Lee KA, Flores RR, Jang IH, Saathoff A, Robbins PD. Immune senescence, immunosenescence and aging. Front Aging. 2022;3:900028.  https://doi.org/10.3389/fragi.2022.900028  PMID: 35821850 
  29. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749-59.  https://doi.org/10.1056/NEJMoa043951  PMID: 15858184 
  30. Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574-83.  https://doi.org/10.1016/j.jacc.2018.02.013  PMID: 29622165 
  31. Childs A, Zullo AR, Joyce NR, McConeghy KW, van Aalst R, Moyo P, et al. The burden of respiratory infections among older adults in long-term care: a systematic review. BMC Geriatr. 2019;19(1):210.  https://doi.org/10.1186/s12877-019-1236-6  PMID: 31382895 
  32. Instituto de Mayores y Servicios Sociales. Ministerio de Derechos Sociales y Agenda 2030. Informe del grupo de trabajo COVID 19 y residencias. Vers. Final. [Report from the working group on COVID-19 and nursing homes. Final version]. Madrid: Ministerio de Derechos Sociales; 2020. Spanish. Available from: https://imserso.es/documents/20123/117116/gtcovid_residencias_vf.pdf
  33. Navascués A, Casado I, Pérez-García A, Aguinaga A, Martínez-Baz I, Floristán Y, et al. Detection of respiratory viruses in deceased persons, Spain, 2017. Emerg Infect Dis. 2018;24(7):1331-4.  https://doi.org/10.3201/eid2407.180162  PMID: 29912695 
  34. Moreno-Iribas C, Sayon-Orea C, Delfrade J, Ardanaz E, Gorricho J, Burgui R, et al. Validity of type 2 diabetes diagnosis in a population-based electronic health record database. BMC Med Inform Decis Mak. 2017;17(1):34.  https://doi.org/10.1186/s12911-017-0439-z  PMID: 28390396 
  35. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment of Respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis. 2023;228(2):173-84.  https://doi.org/10.1093/infdis/jiad012  PMID: 36661222 
Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016/17 to 2019/20
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Noelia+Vera-Punzano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vera-Punzano Noelia</a>, <a href="/search?value1=Camino+Trobajo-Sanmart%C3%ADn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Trobajo-Sanmartín Camino</a>, <a href="/search?value1=Ana+Navascu%C3%A9s&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Navascués Ana</a>, <a href="/search?value1=Aitziber+Echeverria&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Echeverria Aitziber</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=Carmen+Ezpeleta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezpeleta Carmen</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a></span>. Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016/17 to 2019/20. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(10):pii=2400364. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.10.2400364" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.10.2400364</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 07 Jun 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 09 Sept 2024 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.10.2400364
/content/10.2807/1560-7917.ES.2025.30.10.2400364
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error